Physician profile
Barry Izenstein
NPI 1346237583
$6,742.64
in general payments reported to CMS, 2019-2025
43 companies · $40.27 in 2025
The $40.27 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,547 · 2020: $751 · 2021: $1,274 · 2022: $1,084 · 2023: $1,364 · 2024: $681 · 2025: $40.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,026 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,026.41 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,227.18 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Amgen INC. | $817.35 | 2019-2024 | Repatha, Prolia, Evenity |
| Sanofi-Aventis U.S. LLC | $630.03 | 2019-2023 | |
| Novo Nordisk INC | $469.98 | 2019-2024 | Ozempic, Rybelsus, Sogroya |
| Astrazeneca Pharmaceuticals Lp | $433.86 | 2019-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $282.06 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.39 | 2020-2024 | Jardiance, Tradjenta |
| Abbott Laboratories | $238.14 | 2019-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $204.17 | 2019-2021 | |
| Radius Health, INC. | $176.71 | 2019-2024 | |
| Amarin Pharma, INC. | $170.91 | 2020-2021 | |
| Mannkind Corporation | $148.79 | 2019-2023 | Afrezza |
| Pfizer INC. | $135.02 | 2019-2025 | |
| Antares Pharma, INC. | $131.55 | 2019-2024 | Xyosted |
| Lifescan, INC. | $124.23 | 2020-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Izenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.